Efficacy， safety and cost-effectiveness of polyisobutylene-type Gutong plaster in the treatment of osteoarthritis in Chinese adults

JING Tianyu; LIU Chaoyi; LIU Haijiao; ZHONG Gangpeng; HUANG Xiaoqing; XU Wei

doi:10.6039/j.issn.1001-0408.2023.12.13

您当前的位置：

首页 >

文章列表页 >

Efficacy， safety and cost-effectiveness of polyisobutylene-type Gutong plaster in the treatment of osteoarthritis in Chinese adults

更新时间：2025-09-27

- Efficacy， safety and cost-effectiveness of polyisobutylene-type Gutong plaster in the treatment of osteoarthritis in Chinese adults
- ZHONGGUO YAOFANG Vol. 34, Issue 12, Pages: 1478-1482(2023)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.12.13
  CLC： R956;R684.3
- Received：21 October 2022，
  
  Revised：2023-03-20，
  
  Accepted：21 March 2023，
  
  Published：30 June 2023
- 稿件说明：
移动端阅览
经天宇,刘朝一,刘海娇,等.聚异丁烯型骨通贴膏用于中国成人骨关节炎的有效性、安全性和经济性[J].中国药房,2023,34(12):1478-1482.

JING Tianyu,LIU Chaoyi,LIU Haijiao,et al.Efficacy， safety and cost-effectiveness of polyisobutylene-type Gutong plaster in the treatment of osteoarthritis in Chinese adults[J].ZHONGGUO YAOFANG,2023,34(12):1478-1482.
经天宇,刘朝一,刘海娇,等.聚异丁烯型骨通贴膏用于中国成人骨关节炎的有效性、安全性和经济性[J].中国药房,2023,34(12):1478-1482. DOI： 10.6039/j.issn.1001-0408.2023.12.13.

JING Tianyu,LIU Chaoyi,LIU Haijiao,et al.Efficacy， safety and cost-effectiveness of polyisobutylene-type Gutong plaster in the treatment of osteoarthritis in Chinese adults[J].ZHONGGUO YAOFANG,2023,34(12):1478-1482. DOI： 10.6039/j.issn.1001-0408.2023.12.13.

摘要

目的

评估聚异丁烯（PIB）型骨通贴膏（简称“PIB骨通贴膏”）对比非甾体抗炎药（NSAIDs）用于中国骨关节炎成人患者的有效性、安全性和经济性。

方法

基于一项真实世界研究数据，采用倾向评分匹配后，评估PIB骨通贴膏对比3种NSAIDs（塞来昔布、双氯芬酸钠、布洛芬）的疼痛视觉模拟（VAS）评分的下降值、健康效用增加值、疼痛消失时间、关节活动度复常时间以及总不良事件发生情况；采用成本-效用分析法，从全社会角度计算患者使用PIB骨通贴膏相对3种NSAIDs的增量成本-效果比（ICER），并进行敏感性分析。

结果

有效性方面，PIB骨通贴膏组患者的关节活动度复常时间显著长于塞来昔布组，VAS评分下降值显著大于布洛芬但显著小于双氯芬酸钠，疼痛消失时间显著长于双氯芬酸钠组与布洛芬组，健康效用增加值显著低于双氯芬酸钠组（

＜0.05）。安全性方面，PIB骨通贴膏患者的总不良事件发生率及不良事件严重程度与3种NSAIDs比较，差异均无统计学意义（

＞0.05）。经济性方面，与塞来昔布、双氯芬酸钠比较，PIB骨通贴膏为绝对劣势方案；与布洛芬比较，ICER值为178 611.58元/QALY，即现有价格下，若以3倍人均国内生产总值为阈值，PIB骨通贴膏方案具有经济性。敏感性分析结果与基础分析结果一致。

结论

PIB骨通贴膏用于我国骨关节炎患者短期治疗的疗效优于布洛芬，与塞来昔布相当，但不及双氯芬酸钠，安全性与3种NSAIDs一致，其经济性还有待提高。

Abstract

OBJECTIVE

To evaluate the efficacy， safety and cost-effectiveness of polyisobutylene （PIB）-type Gutong plaster （called “PIB Gutong plaster” for short） versus non-steroidal anti-inflammatory drugs （NSAIDs） in the treatment of osteoarthritis in Chinese adults.

METHODS

Based on a real-world study， after propensity score matching， the decrease in pain visual simulation score， utility increase， time to pain resolution， time to return to normal range of motion and total adverse events of PIB Gutong plaster versus three NSAIDs （celecoxib， diclofenac sodium， and ibuprofen） were evaluated. Cost-utility analysis was used to calculate the incremental cost-effectiveness ratio （ICER） of patients using PIB Gutong plaster versus the three NSAIDs from the perspective of the whole society， and sensitivity analysis was carried out.

RESULTS

In terms of effectiveness， the recovery time of joint activity in PIB Gutong plaster group was significantly longer than that in celecoxib group， the decrease in VAS score of PIB Gutong plaster was significantly higher than that of ibuprofen but significantly lower than that of diclofenac sodium； the time of pain disappearance was longer than that in diclofenac sodium group and ibuprofen group， and the increase in health utility was significantly lower than that in diclofenac sodium group （

＜0.05）. In terms of safety， there were no significant differences in the incidence and severity of adverse events of PIB Gutong plaster， compared with the three NSAIDs， without statistical significance （

＜0.05）. In terms of cost-effectiveness， compared with celecoxib and diclofenac sodium， PIB Gutong plaster was dominant. Compared with ibuprofen， the ICER value of PIB Gutong plaster was 178 611.58 yuan/QALY， indicating that at the current price， PIB Gutong plaster was cost-effective if the threshold was

3 times GDP per capita. The results of sensitivity analysis were consistent with those of basic analysis.

CONCLUSIONS

The efficacy of PIB Gutong plaster was better than that of ibuprofen， similar to that of celecoxib， but worse than that of diclofenac sodium， the safety was consistent with the three NSAIDs， and the cost-effectiveness of PIB Gutong plaster needs to be improved.

关键词

Keywords

references

薛庆云，王坤正，裴福兴，等 . 中国40岁以上人群原发性骨关节炎患病状况调查 [J ] . 中华骨科杂志， 2015 ， 35 （ 12 ）： 1206 - 1212 .

中华医学会骨科学分会关节外科学组，中国医师协会骨科医师分会骨关节炎学组，国家老年疾病临床医学研究中心（湘雅医院），等 . 中国骨关节炎诊疗指南：2021年版 [J ] . 中华骨科杂志， 2021 ， 41 （ 18 ）： 1291 - 1314 .

中国标准化协会中医药标准化分会 . 中成药临床应用指南风湿病分册 [M ] . 北京：中国中医药出版社， 2017 ： 165 .

杜婕莹，曾森，王璐，等 . 聚异丁烯骨通贴膏经皮肤给药的安全性研究 [J ] . 中国药房， 2016 ， 27 （ 25 ）： 3512 - 3514 .

赵小庆 . PIB骨通贴膏治疗关节疼痛有效性和安全性的临床研究 [D ] . 哈尔滨：哈尔滨商业大学， 2020 .

刘中原 . 局部晚期鼻咽癌多西他赛联合顺铂和氟尿嘧啶诱导化疗序贯顺铂同期放化疗中以奈达铂替代顺铂的回顾性倾向评分匹配研究 [D ] . 广州：广州医科大学， 2020 .

ZHUO L ， XU L ， YE J T ， et al . Time trade-off value set for EQ-5D-3L based on a nationally representative Chinese population survey [J ] . Value Health ， 2018 ， 21 （ 11 ）： 1330 - 1337 .

中国中西医结合学会骨伤科专业委员会 . 膝骨关节炎中西医结合诊疗指南 [J ] . 中华医学杂志， 2018 ， 98 （ 45 ）： 3653 - 3658 .

孙斌，王子婧，曹阳，等 . 非甾体抗炎药治疗我国中老年骨关节炎疗效和安全性的网状Meta分析 [J ] . 药学实践杂志， 2021 ， 39 （ 3 ）： 259 - 266 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 14 .

国家统计局 . 中华人民共和国2020年国民经济和社会发展统计公报 [EB/OL ] . [ 2022-10-11 ] . http：//www.gov.cn/xinwen/2021-02/28/content_5589283.htm http://www.gov.cn/xinwen/2021-02/28/content_5589283.htm .

国家统计局 . 2021年居民收入和消费支出情况 [EB/OL ] . [ 2022-10-11 ] . http：//big5.www.gov.cn/gate/big5/www.gov.cn/shuju/2022-01/17/content_5668748.htm http://big5.www.gov.cn/gate/big5/www.gov.cn/shuju/2022-01/17/content_5668748.htm .

《中成药治疗优势病种临床应用指南》标准化项目组 . 中成药治疗膝骨关节炎临床应用指南：2020 年[J ] . 中国中西医结合杂志， 2021 ， 41 （ 5 ）： 522 - 533 .

Views

303

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of Huangkui capsule combined with cyclophosphamide and prednisone in the treatment of IgA nephropathy with renal insufficiency

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Overview of systematic evaluation of anti-VEGF drugs in the treatment of diabetic macular oedema

Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren syndrome

Clinical observation of doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children under 8 years of age

Related Author

JIANG Yan

ZHANG Ming

LIU Guoxin

ZHAO Chenyang

WANG Wanwan

YE Jun

CHENG Hai

YAO Wei

Related Institution

Dept. of Pharmacy， the Second Affiliated Hospital of Dalian Medical University

Dept. of Hematology， the Affiliated Hospital of Xuzhou Medical University

Dept. of Hematology， the Third People’s Hospital of Bengbu

College of Basic Medical Sciences， Gansu University of Chinese Medicine

Infection Management Section， Gansu Provincial People’s Hospital

⁰